# Ipamorelin Research: Mechanism, Studies, and the Honest Record > Ipamorelin research, plainly: the GHS-R1a mechanism, the founding studies, the human PK and the failed trial, the 2024 ferret data, and the CJC-1295 stacking science. Receptor to readout, every number cited. Including the parts the marketing leaves out. ## Start here Ipamorelin research comes down to one clean mechanism and a short list of studies that actually hold up. The mechanism: ipamorelin flips on a receptor called GHS-R1a — the same one the hunger hormone ghrelin uses — which makes the pituitary gland fire off a pulse of growth hormone (GH). What makes it notable is what it *doesn't* do: it leaves the stress hormones mostly alone. The study record is honest but thin. There's a founding 1998 paper that defined the compound, a 1999 human study that measured how fast it clears, a 2014 human trial that failed, some rat bone and a 2024 ferret study. That's most of the real evidence. A lot of the rest of what you'll read online about ipamorelin is extrapolated from related peptides — which is fine as long as someone tells you that's what's happening. We tell you. Each major finding below gets its own heading and its own citation. ## The mechanism: a clean pull on one receptor Ipamorelin selectively activates the **GHS-R1a receptor** (the ghrelin / growth hormone secretagogue receptor) on the pituitary's GH-producing cells, the somatotrophs [1]. Activation runs through the Gq/PLC pathway, raises intracellular calcium, and releases a GH pulse. Because it works through this receptor and not the GHRH receptor, it's complementary to GHRH analogs — which is the entire rationale for stacking it with one. The defining result, from Raun and colleagues in 1998: in primary rat pituitary cells, anaesthetised rats, and conscious swine, ipamorelin released GH potently (swine ED50 = 2.3 nmol/kg vs 3.9 nmol/kg for GHRP-6), yet did not raise ACTH or cortisol above the level seen with GHRH even at doses more than 200-fold above its GH threshold [1]. That single comparison is why "selective" is in its name. One caveat the paper itself is clear about: this characterization was acute, not chronic. ## What is ipamorelin peptide Ipamorelin peptide is a wholly synthetic pentapeptide — five amino acids: Aib-His-D-2-Nal-D-Phe-Lys-NH2 [1]. It is not something the body makes; it's engineered to mimic ghrelin's action at the GHS-R1a receptor. The non-natural amino acid Aib (alpha-aminoisobutyric acid) at position one, plus two D-form residues, make it resistant to the enzymes that would otherwise chew it up. Its molecular weight is about 712 daltons. It was derived from the earlier peptide GHRP-1 by removing a central two-amino-acid segment [1]. In short: a small, stable, lab-built key cut specifically to fit the ghrelin lock and trigger a GH pulse. ## The human data: a clean half-life and a failed trial Two human datasets carry most of the weight. The first, a 1999 PK/PD study in healthy men, gave five IV doses (4.21 to 140.45 nmol/kg) and found dose-proportional kinetics with a terminal half-life of about 2 hours, clearance of 0.078 L/h/kg, and a GH response that peaked as a single discrete pulse around 40 minutes after dosing [2]. That's the source of nearly every "ipamorelin half-life" figure you'll see quoted. The second is the one that matters most and gets cited least. The only published Phase 2 RCT (NCT00672074) enrolled 114 adults having bowel resection and gave 0.03 mg/kg IV twice daily for up to 7 days for postoperative ileus [3]. It **missed its primary endpoint**: median time to first tolerated meal was 25.3 hours with ipamorelin versus 32.6 hours with placebo (p=0.15) [3]. No ipamorelin-specific safety signal showed up in that short window — adverse events hit 87.5% of the ipamorelin arm versus 94.8% of placebo — but efficacy simply wasn't demonstrated, and development stopped [3]. When a site tells you ipamorelin is "clinically studied," this is the study. It didn't work. ## The animal record: bone, body weight, and a 2024 data point In adult female rats, 15 days of subcutaneous ipamorelin (18, 90, and 450 micrograms/day, divided three times daily) raised the longitudinal bone-growth rate dose-dependently — from 42 micrometers/day on vehicle to 44, 50, and 52 at the three doses — with no change in total IGF-1, IGF-binding proteins, or bone-turnover markers [4]. The flat IGF-1 is interesting: it points to a partly local, GH-pulse-driven skeletal effect rather than a systemic IGF-1 surge. The most recent published in-vivo study is from 2024, in ferrets. Intraperitoneal ipamorelin (1 to 3 mg/kg) inhibited cisplatin-induced body-weight loss by about 24% on the last day of the delayed phase (48 to 72 hours) — but had no anti-emetic effect on either acute or delayed chemotherapy-induced vomiting, in contrast to central anamorelin, which cut acute emesis by 60% [5]. It's the freshest, most defensible recent finding, and it frames ipamorelin's plausible niche as metabolic and peripheral, not the broad anti-aging story. ## Ipamorelin cjc-1295 The **ipamorelin cjc-1295** pairing is the most-searched thing about this compound, so here's the science honestly. Ipamorelin (a GHRP — it hits the ghrelin receptor) and CJC-1295 (a GHRH analog — it hits a different receptor) release GH by complementary mechanisms, which is the textbook rationale for combining a GHRP with a GHRH analog. The supporting evidence is class-level, not combination-specific: chronic GHRP-2 or GHRH administration over 7 to 30 days converted an additive GH response into a synergistic one in younger and older adults [9]; hexarelin plus GHRH-(1-29) stayed synergistic even under high somatostatin tone that blunted GHRH alone [10]; and in rats, exogenous GHRH plus a GHRP produced GH peaks greater than the sum of each alone [11]. Mechanistically, endogenous GHRH is *required* for full GHRP activity — blocking it attenuates the GH response [12]. So the rationale is real. What does **not** exist is a trial of CJC-1295 + ipamorelin, as a combination, for any outcome [3]. The stack rests on separate single-agent pharmacology. ## What is cjc 1295 ipamorelin In plain terms: **cjc 1295 ipamorelin** is a two-peptide pairing of a GHRH analog (CJC-1295) and a GHRP (ipamorelin) used together to push a larger GH pulse than either tends to alone. CJC-1295 raises the baseline GH-releasing drive through the GHRH receptor; ipamorelin adds a sharp pulse through the ghrelin receptor and, unlike older GHRPs, does it without spiking cortisol or prolactin [1]. The class-level synergy studies above are why people pair them [9][10]. The honest caveat repeats: the pairing itself has never been tested as a unit in a controlled trial [3], and this site covers pure ipamorelin — the combination is here because the questions demand it, not because we endorse a protocol. ## Does cjc-1295 ipamorelin work "Work" depends entirely on what you're asking it to do. For releasing GH, the mechanism is well established and the class-level synergy is documented [9][10][11]. For any *clinical outcome* — fat loss, muscle gain, anti-aging, recovery — there is no controlled human trial of the combination demonstrating it [3], and ipamorelin's own solo human trial failed its endpoint [3]. So: it reliably does the pharmacological thing (a GH pulse), and there is no trial-grade proof it delivers the body-composition or wellness results it's marketed for. Animal signals (bone growth, blunted weight loss) are real but don't translate automatically to humans [4][5]. --- It says shop; it sells nothing — just a zine pinning ipamorelin's never-approved, pulled-from-the-503A-list, banned-in-sport record next to what the studies actually measured.